Quince Therapeutics announces 1-for-20 reverse stock split effective June 29, 2026

Quince Therapeutics, Inc.

Stockholders approved reverse split on June 11, 2026; board set ratio at 1-for-20.
Certificate of Amendment filed with Delaware Secretary of State on June 26, 2026; effective June 29 at 11:59 pm ET.
Pre-split shares outstanding: 19,559,257; post-split approx 977,963; CUSIP changes to 22053A305.
Ticker remains QNCX; options and warrants proportionally adjusted; fractional shares cashed out.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.